Skip to main content
. 2023 Nov 27;63(1):9–18. doi: 10.1021/acs.biochem.3c00433

Figure 4.

Figure 4

(A) Digest assay with ME/CFS_11 (Figure 1) before and after addition of whole glatiramer acetate (GA), 30 μM final; (B) GA fractionated using size-exclusion chromatography (top chromatogram with fraction demarcations (vertical lines)) corresponding to degree of inhibition in the bar graph directly below for sample ME/CFS_11; (C) comparison of four class-specific protease inhibitors on preventing ME/CFS_12 Ab digest of MBP; each inhibitor was tested at 0.1 and 0.01 μg (1.22 and 0.122 μM final, respectively); and (D) digest assay comparing inhibition by GA and three random peptides: (1) MBP only, (2) ME/CFS_12 Ab + MBP, (3) GA (30 μM), (4) peptide YY, (5) gastrin releasing peptide, and (6) influenza hemagglutinin peptide (each at 30 μM final concentration with 3 μg Ab and 1 μg MBP).